Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R5HK
|
|||
| Former ID |
DNC001353
|
|||
| Drug Name |
Sodium valproate
|
|||
| Synonyms |
Sodium valproate; Sodium 2-propylpentanoate; 1069-66-5; Valproate sodium; Valproic acid sodium salt; Labazene; Eurekene; Orfiril; Valproic acid sodium; Epilim; Valerin; Natrium valproat; Sodium 2-propylvalerate; 2-Propylvaleric acid sodium salt; Pentanoic acid, 2-propyl-, sodium salt; 2-Propylpentanoic acid sodium salt; DEPACON; Sodium dipropylacetate; Dipropylacetate sodium; Sodium bispropylacetate; Valproinsaeure, natrium; Sodium n-dipropylacetate; UNII-5VOM6GYJ0D; Valproic Acid, Sodium Salt; Valproic Acid (sodium salt); Sodium 2
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C8H15NaO2
|
|||
| Canonical SMILES |
CCCC(CCC)C(=O)[O-].[Na+]
|
|||
| InChI |
1S/C8H16O2.Na/c1-3-5-7(6-4-2)8(9)10;/h7H,3-6H2,1-2H3,(H,9,10);/q;+1/p-1
|
|||
| InChIKey |
AEQFSUDEHCCHBT-UHFFFAOYSA-M
|
|||
| CAS Number |
CAS 1069-66-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
3140830, 7847775, 8149581, 11112073, 11533347, 14772519, 17405448, 24277744, 26611975, 26679345, 26747599, 26747600, 26759724, 29282141, 46580918, 50062093, 50106736, 50112990, 53777995, 56311201, 56311934, 56313007, 57260140, 57264261, 57264447, 57328420, 57381838, 76227302, 85089488, 85171019, 85231324, 91011417, 92124425, 92304110, 92307562, 99301361, 99436930, 103165510, 109613260, 117375016, 121361484, 124637890, 124757047, 124799386, 124881887, 124881888, 125163851, 125333638, 126617481, 134979762
|
|||
| ChEBI ID |
CHEBI:9925
|
|||
| ADReCS Drug ID | BADD_D02328 | |||
| SuperDrug ATC ID |
N03AG01
|
|||
| SuperDrug CAS ID |
cas=000099661
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | GABA transaminase (ABAT) | Target Info | Inhibitor | [1] |
| BioCyc | GABA shunt | |||
| Valine degradation | ||||
| Beta-alanine degradation | ||||
| 4-aminobutyrate degradation | ||||
| KEGG Pathway | Alanine, aspartate and glutamate metabolism | |||
| Valine, leucine and isoleucine degradation | ||||
| beta-Alanine metabolism | ||||
| Propanoate metabolism | ||||
| Butanoate metabolism | ||||
| Metabolic pathways | ||||
| GABAergic synapse | ||||
| Panther Pathway | Aminobutyrate degradation | |||
| Pyrimidine Metabolism | ||||
| Gamma-aminobutyric acid synthesis | ||||
| Pathwhiz Pathway | Aspartate Metabolism | |||
| Glutamate Metabolism | ||||
| Beta-Alanine Metabolism | ||||
| Valine, Leucine and Isoleucine Degradation | ||||
| Propanoate Metabolism | ||||
| WikiPathways | GABA synthesis, release, reuptake and degradation | |||
| Alanine and aspartate metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Influence of a GABA transaminase inhibitor on central nervous system oxygen toxicity. Aviat Space Environ Med. 1978 Jul;49(7):877-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.